IRD Company Profile and Key Details

IRD has shown sold momentum, gaining 10.24% over the past week and 20.86% over the past quarter, though year-to-date performance is up 12.44%. Short-term trend indicators are bearishly aligned (SMA20 25.68%, SMA50 35.12%, SMA200 92.26%). The stock’s 14-day RSI is 68.41 (firm momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.31% below its high and over 363.08% above its low. Average 10-day trading volume of 1.36 million shares is significantly above the 3-month average of 653.61 thousand, indicating heightened recent market interest.

Opus Genetics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.12. This means the shares are trading below this model’s fair value.

Opus Genetics, Inc. has 59.91 million shares outstanding. The public float is 30.28 million shares, elevated short interest at 0.45% of float. This equals 255.25 thousand shares. The short ratio is 1.05 days. Institutional investors hold 35.4% of the float. Insiders own 21.58%. Foundation Fighting Blindness Retinal Degeneration Fund holds 5.49 million shares, Magrath George has 599.15 thousand shares and YERXA BENJAMIN R has 342.80 thousand shares. Over the past six months, insider transactions show balanced activity. They sold 4.00 million shares across 1 transactions.

Opus Genetics, Inc. (NASDAQ:IRD) closed at $3.01 USD, gaining $0.43 (16.67%) from the previous close of $2.58. The stock is currently within 5% of its 52-week high $0.65 and $3.08. With a market capitalization of about $207.58 million, Opus Genetics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.59). Key stats such as the average daily volume over the past year has been around 600.92 thousand shares, trading with heavier-than-usual volume. Headquartered in Durham, MI, Opus Genetics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO George Magrath, the company employs approximately 18 people and listed since January 19, 2015. Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.

Opus Genetics, Inc. generated EPS of -$1.72 over the past year. Five-year average earnings growth is 24.32%. Wall Street analysts project EPS growth of 41.17% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $5.00. The high target offers 199.0% upside. The low target suggests 66.11% downside. The mean target is $7.83. This offers 160.13% upside. Opus Genetics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 105.91%. The prior quarter beat by -52.0%. Over the last six quarters, Apple has recorded several small beats. These include 20.0% in August 13, 2024.

Opus Genetics, Inc. trades at a P/E ratio of -3.1, slightly below the S&P 500 average, with a price-to-sales ratio of 14.11 and a price-to-book ratio of 35.43 reflecting a rich premium to book value. The P/FCF stands at -6.28, also above market averages. Compared to sector medians, Opus Genetics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Opus Genetics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 52.82%, reaching $4.60 by May 06, 2026, with a range of $4.57 to $4.64. 1-Year Outlook: Projected gain of 747.18%, with price at $25.50 by February 05, 2027, within a range of $25.50 to $25.60.

Opus Genetics, Inc. (NASDAQ:IRD) shares are up 12.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Opus Genetics, Inc. trading at a premium to the broader market with a P/E of -3.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.85, suggesting 160.8% upside.